| __timestamp | Corcept Therapeutics Incorporated | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 882000 | 520990000000 |
| Thursday, January 1, 2015 | 1361000 | 535405000000 |
| Friday, January 1, 2016 | 2058000 | 558755000000 |
| Sunday, January 1, 2017 | 3554000 | 495921000000 |
| Monday, January 1, 2018 | 5215000 | 659690000000 |
| Tuesday, January 1, 2019 | 5504000 | 1089764000000 |
| Wednesday, January 1, 2020 | 5582000 | 994308000000 |
| Friday, January 1, 2021 | 5281000 | 1106846000000 |
| Saturday, January 1, 2022 | 5385000 | 1244072000000 |
| Sunday, January 1, 2023 | 6481000 | 1431505000000 |
| Monday, January 1, 2024 | 1431505000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. This analysis delves into the cost of revenue trends for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated from 2014 to 2023. Takeda, a global leader, has seen its cost of revenue grow by approximately 175% over the decade, peaking at 1.43 trillion in 2023. This reflects its expansive operations and market reach. In contrast, Corcept, a niche player, experienced a 635% increase, reaching 6.48 million in 2023, highlighting its strategic growth in specialized therapies.
The data reveals Takeda's consistent upward trajectory, with a notable surge post-2018, likely due to strategic acquisitions and product launches. Meanwhile, Corcept's growth, though smaller in absolute terms, underscores its focused approach in the biotech sector. Missing data for 2024 suggests ongoing developments, making future trends worth watching.
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Corcept Therapeutics Incorporated
Annual Revenue Comparison: Takeda Pharmaceutical Company Limited vs Corcept Therapeutics Incorporated
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Xencor, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for BeiGene, Ltd. and Corcept Therapeutics Incorporated
Insmed Incorporated vs Corcept Therapeutics Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Celldex Therapeutics, Inc.'s Expenses